Reduced COVID-19 vaccine response in patient treated with dupilumab for IgG4-related disease

Dupilumab is a novel anti–IL-4 receptor-α mAb that targets the signaling pathways of IL-4 and IL-13. Thus far, the data about adequate humoral immune response after vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in patients who are taking dupilumab have been limited...

Descripción completa

Detalles Bibliográficos
Autores principales: Abadeh, Armin, Lee, Jason Kihyuk
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9598042/
https://www.ncbi.nlm.nih.gov/pubmed/36313899
http://dx.doi.org/10.1016/j.jacig.2022.08.007
Descripción
Sumario:Dupilumab is a novel anti–IL-4 receptor-α mAb that targets the signaling pathways of IL-4 and IL-13. Thus far, the data about adequate humoral immune response after vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in patients who are taking dupilumab have been limited.

Ejemplares similares